Archive for the ‘Cytori Therapeutics’ Category

Cytori Therapeutics, Inc

December 15th, 2015 | Posted in 2015, Cytori Therapeutics

San Diego’s Cytori Therapeutics, Inc. signed a 3 year distribution nonexclusive agreement with Worthington Biochemical Corp., NJ, to place the Celase GMP enzyme in research markets in the U.S. and select locations internationally. Celase GMP is an enzyme containing a blend of particular enzymes, collagenase and neutral protease, and buffer salts for in vitro dissociation […]

Cytori Therapeutics

May 11th, 2015 | Posted in 2015, Cytori Therapeutics

Chinese regulators cleared Cytori Therapeutics, San Diego, to market  its Celution System, a regenerative cell technology system.

Cytori Therapeutics

November 20th, 2013 | Posted in 2013, Cytori Therapeutics

Cytori Therapeutics – Recently announced that it could get as much as $531-million after licensing its regenerative cell technology to Lorem Vascular.  The arrangement allows Lorem to market Cytori’s cell therapy in China, Hong Kong, Malaysia, Singapore and Australia as a treatment for cardiovascular and renal conditions and diabetes.  The companies said they expect to […]

Cytori Therapeutics Inc

November 8th, 2012 | Posted in 2012, Cytori Therapeutics

Cytori Therapeutics Inc. – San Diego:  Announced an investigator-sponsored and funded clinical study evaluating its cell therapy as a potential treatment for scleroderma has been approved to start in France.  Scleroderma is a rare autoimmune disorder that results in an oveproduction of collagen in the skin and vital organs.

Cytori Therapeutics

February 2nd, 2011 | Posted in 2011, Cytori Therapeutics

Cytori Therapeutics., a company that specializes in tissue regeneration technology, announced that it has received European approval to begin a study of its Celution One System for treating patients after severe heart attack.  Cytori already markets Celution 800 System in Europe, where it is used for breast reconstruction, would repair and several otehr asthetic surgical […]

Xenonics Holdings Inc

December 15th, 2010 | Posted in Cytori Therapeutics

Xenonics Holdings Inc., will receive an investment of $10-million from Japanese drugmaker “Astellas Pharma Inc.” as part of an agreement to evaluate the use of stem and regenerative cells for treating serious illnesses.

Cytori Therapeutics, San Diego

January 27th, 2010 | Posted in Cytori Therapeutics

Cytori Therapeutics, San Diego, has been issued a new patent covering the company’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grants into patients.  The new patent expands upon the company’s previously issued patent relating to automated methods of creating cell-enriched fat grants.  Cytori’s intellectual property portfolio currently includes 19 issued U.S. and international […]